980 results match your criteria: "Neurocentre[Affiliation]"
Neurol Neuroimmunol Neuroinflamm
March 2025
Department of Neurology with Institute of Translational Neurology, University Hospital 4 Münster, Germany.
Sci Rep
December 2024
GIN, IMN-UMR5293, CEA, CNRS, Université de Bordeaux, Bordeaux, France.
Cerebral microbleeds (CMB) represent a feature of cerebral small vessel disease (cSVD), a prominent vascular contributor to age-related cognitive decline, dementia, and stroke. They are visible as spherical hypointense signals on T2*- or susceptibility-weighted magnetic resonance imaging (MRI) sequences. An increasing number of automated CMB detection methods being proposed are based on supervised deep learning (DL).
View Article and Find Full Text PDFInt J Mol Sci
November 2024
Neurocentre Magendie INSERM U1215, Université de Bordeaux, 33000 Bordeaux, France.
In amyotrophic lateral sclerosis (ALS), early mitochondrial dysfunction may contribute to progressive motor neuron loss. Remarkably, the ectopic expression of the Orthobornavirus bornaense type 1 (BoDV-1) X protein in mitochondria blocks apoptosis and protects neurons from degeneration. Therefore, this study examines the neuroprotective effects of X protein in an ALS mouse model.
View Article and Find Full Text PDFNutrients
December 2024
Grupo de Neuropsicofarmacología, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Unidades Clínicas de Neurología y Salud Mental, 29010 Málaga, Spain.
Background/objectives: Alzheimer's disease (AD), a leading cause of dementia, lacks effective long-term treatments. Current therapies offer temporary relief or fail to halt its progression and are often inaccessible due to cost. AD involves multiple pathological processes, including amyloid beta (Aβ) deposition, insulin resistance, tau protein hyperphosphorylation, and systemic inflammation accelerated by gut microbiota dysbiosis originating from a leaky gut.
View Article and Find Full Text PDFEndocrine
December 2024
Department of Neurosurgery, Hôpitaux Universitaires de Genève (HUG), Geneva, Switzerland.
Purpose: Transient arginine vasopressin deficiency (AVP-D), previously called diabetes insipidus, is a well-known complication of transsphenoidal pituitary surgery (TPS) with no definite predictive biomarker to date making it difficult to anticipate. While oxytocin (OXT) was previously suggested as a possible biomarker to predict syndrome of inappropriate diuresis (SIAD)-related hyponatraemia after TPS, its secretion in patients presenting with AVP-D remains poorly understood. We therefore hypothesized that OXT might present a different secretion in the case of AVP-D which would support its potential as an early biomarker of AVP-D.
View Article and Find Full Text PDFJ Neurochem
January 2025
Department of Neurology, F.M. Kirby Neurobiology Center, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Neuron-glia interactions are fundamental to the development and function of the nervous system. During development, glia, including astrocytes, microglia, and oligodendrocytes, influence neuronal differentiation and migration, synapse formation and refinement, and myelination. In the mature brain, glia are crucial for maintaining neural homeostasis, modulating synaptic activity, and supporting metabolic functions.
View Article and Find Full Text PDFClin Transl Med
December 2024
Université de Poitiers, INSERM IRMETIST U1313, CHU de Poitiers, Service de Biochimie, Poitiers, France.
: Among strategies to limit ischemia/reperfusion (IR) injuries in transplantation, cell therapy using stem cells to condition/repair transplanted organs appears promising. We hypothesized that using a cell therapy based on extracellular vesicles (EVs) derived from urine progenitor cells (UPCs) during hypothermic and normothermic machine perfusion can prevent IR-related kidney damage. We isolated and characterized porcine UPCs and their extracellular vesicles (EVs).
View Article and Find Full Text PDFBrain Res Bull
December 2024
Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK; School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK. Electronic address:
Recent clinical trials targeting tau protein aggregation have heightened interest in tau-based therapies for dementia. Success of such treatments depends crucially on translation from non-clinical animal models. Here, we present the age profile of the PLB2 knock-in model of fronto-temporal dementia in terms of cognition, and by utilising a directly translatable magnetic resonance imaging approach.
View Article and Find Full Text PDFTrends Endocrinol Metab
December 2024
University of Bordeaux, INSERM, Neurocentre Magendie, U1215, F-33000, Bordeaux, France. Electronic address:
It has long been thought that the functional identity of mammalian brain neurons is programmed during development and remains stable throughout adult life; however, certain populations of neurons continue to express active regulators of neuronal identity into adulthood. Prolonged exposure to diet-induced metabolic stress induces features of neuronal identity modification in adult mice, and maladaptive changes in neuronal identity maintenance have been linked to cognitive impairment in humans suffering from neurodegenerative diseases often associated with obesity. Here we discuss how, by unraveling the neurological roots of obesity, we may solve the puzzle of whether mammalian brain neurons retain identity plasticity into adulthood, while advancing knowledge of the pathogenic mechanisms at the interface of metabolic and neurodegenerative disorders.
View Article and Find Full Text PDFJ Neurol Neurosurg Psychiatry
December 2024
Department of Neurology, The Alfred Hospital, Melbourne, Victoria, Australia.
Background: Effectiveness of disease-modifying treatment (DMT) in people affected by primary progressive multiple sclerosis (PPMS) is limited. Whether specific subgroups may benefit more from DMT in a real-world setting remains unclear. Our aim was to investigate the potential effect of DMT on disability worsening among patients with PPMS stratified by different disability trajectories.
View Article and Find Full Text PDFJ Neuroradiol
December 2024
Service de Radiologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France; Creatis LRMN, CNRS UMR 5220, Université Claude Bernard Lyon 1, INSERM U630, Lyon, France.
Background: Currently, there are no available recommendations or guidelines on how to perform MRI monitoring in the management of neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The issue is to determine a valuable MRI monitoring protocol to be applied in the management of NMOSD and MOGAD, as previously proposed for the monitoring of multiple sclerosis.
Objectives: The objectives of this work are to establish proposals for a standardized and feasible MRI acquisition protocol, and to propose control time points for systematic MRI monitoring in the management of NMOSD and MOGAD.
Neurology
December 2024
From the Department of Neurology (H.-P.H.), UKD, Centre of Neurology and Neuropsychiatry and LVR-Klinikum, Heinrich-Heine University Düsseldorf, Germany; Brain and Mind Centre (H.-P.H.), University of Sydney, Australia; Department of Neurology (H.-P.H.), Palacky University Olomouc, Czech Republic; Department of Neurology (R.H.B.B.), Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, NY; Department of Neurology (T.B.), Medical University of Vienna, Comprehensive Center for Clinical Neurosciences and Mental Health, Austria; Mellen Center for MS (R.A.B.), Cleveland Clinic, OH; Neurocentre Magendie INSERM (B.B.), Université de Bordeaux, France; Department of Neurology (W.M.C.), Sir Charles Gairdner Hospital, Perron Institute for Neurological and Translational Science, The University of Western Australia, Nedlands; Department of Medicine and the Ottawa Hospital Research Institute (M.S.F.), University of Ottawa, Ontario, Canada; Department of Neurology (T.H.), Akershus University Hospital, Lørenskog; Institute of Clinical Medicine (T.H.), University of Oslo, Norway; Department of Neurology (R.K.), Hacettepe University Faculty of Medicine, Ankara, Turkey; Centre d'Esclerosi Mútiple de Catalunya (Cemcat) (C.N.), Vall d'Hebron Hospital Universitari, Barcelona, Spain; Department of Medical and Surgical Sciences and Advanced Technologies (F.P.), GF Ingrassia, Neuroscience Section and Multiple Sclerosis Centre, University of Catania PO Policlinico G Rodolico, Italy; Loyola University Chicago (A.P.R.), IL; Department of Neurology (L.V.), AZ Sint-Jan Brugge-Oostende, Belgium; Department of Neurology (T.V.), University of Colorado School of Medicine, Aurora; Medical Image Analysis Center (MIAC AG) (J.W.), Department of Biomedical Engineering, University of Basel; F. Hoffmann-La Roche Ltd (J.W., S.C., K.K., T.K., I.K., C.R., G.-A.T.), Basel, Switzerland; and Department of Neurology (J.K.), VU University Medical Centre, Amsterdam, the Netherlands.
Background And Objectives: Early treatment of multiple sclerosis (MS) reduces disease activity and the risk of long-term disease progression. Effectiveness of ocrelizumab is established in relapsing MS (RMS); however, data in early RMS are lacking. We evaluated the 4-year effectiveness and safety of ocrelizumab as a first-line therapy in treatment-naive patients with recently diagnosed relapsing-remitting MS (RRMS).
View Article and Find Full Text PDFMult Scler
December 2024
Univ Rennes, EHESP, CNRS, Inserm, Arènes-UMR 6051, RSMS (Recherche sur les Services et Management en Santé)-U 1309, Rennes, France.
Background: We hypothesized that differences in access to disease-modifying treatments (DMTs) could explain the association between socioeconomic status and disability progression in multiple sclerosis (MS).
Objective: This study aimed to analyze the association between education level and DMT use in France.
Methods: All patients from OFSEP network with MS onset over 1996-2014 and aged ⩾ 25 years at onset were included.
Mult Scler
November 2024
Univ Rennes, EHESP, CNRS, Inserm, Arènes-UMR 6051, RSMS (Recherche sur les Services et Management en Santé)-U 1309, Rennes, France.
Background: Studies have reported an association between socioeconomic status and disability progression in multiple sclerosis (MS), but findings using the pre-MS individual socioeconomic status are missing.
Objective: The objective was to investigate the association between education level and disability progression.
Methods: All Observatoire Français de la Sclérose en Plaques (OFSEP) patients with MS clinical onset over 1960-2014, and aged ⩾25 years at MS onset were included.
Epilepsia
November 2024
Department of Neurology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Écublens, Switzerland.
General anesthesia (GA) earlier than recommended (as first- or second-line treatment) was recently described to improve status epilepticus (SE) outcome. We aimed to assess the impact of early GA on outcome in matched groups. Data from a multicenter, prospective cohort of 1179 SE episodes in 1049 adults were retrospectively analyzed.
View Article and Find Full Text PDFMol Metab
November 2024
University of Bordeaux, INSERM, Neurocentre Magendie, U1215, F-33000, Bordeaux, France. Electronic address:
Objective: Steroidogenic factor-1 (SF1) neurons of the ventromedial hypothalamus play key roles in the regulation of food intake, body weight and glucose metabolism. The bile acid receptor Takeda G protein-coupled receptor 5 (TGR5) is expressed in the hypothalamus, where it determines some of the actions of bile acids on food intake and body weight through still poorly defined neuronal mechanisms. Here, we examined the role of TGR5 in SF1 neurons in the regulation of energy balance and glucose metabolism.
View Article and Find Full Text PDFNeurology
December 2024
From the Department of Human Neuroscience (E.N., S.L., D.T.), Sapienza University of Rome; Stroke Unit (E.N., F.S.), Ospedale dei Castelli, Ariccia (RM); Department of NEUROFARBA (G.P.), Neuroscience Section, University of Florence; Stroke Unit (A.C., M.D.M.), Policlinico Umberto I, Sapienza University of Rome; Neurology and Stroke Unit (V.S., T.T.), S. Corona Hospital, Pietra Ligure, Italy; Interventional Neurovascular Unit (N. Limbucci), Careggi University Hospital; Careggi University Hospital (P.N.), Florence; AUSL Romagna Cesena (M.R.); Neurologia e Stroke Unit Ospedale Bufalini Cesena (M.L.); UO Neuroradiologia (M. Cosottini); Neurological Institute (G.O.), Azienda Ospedaliero Universitaria Pisana; Dipartimento di Neuroscienze (M.B.), Universitá di Torino; A.O. Cittá della Salute (P.C.), Torino; UO Neuroradiologia (S.V.); Neurologia-Stroke Unit (G. Bigliardi), Ospedale Civile di Baggiovara - AOU di Modena; UOC Neuroradiologia diagnostica e terapeutica AOU Senese (S.C.); UOC Stroke Unit AOU Senese (R.T.), Siena; Dipartimento di Biomedicina e Prevenzione - UOSD radiologia interventistica (V.D.R.); Department of Systems Medicine (M.D.), University of Rome Tor Vergata; IRCCS Istituto di Scienze Neurologiche di Bologna - UOC Neuroradiologia Ospedale Bellaria (L.S.); IRCCS Istituto di Scienze Neurologiche di Bologna (A.Z.), Department of Neurology and Stroke Center, Maggiore Hospital; UOC Neuroradiologia AOU "G. Martino" Messina (M.V.); UOSD Stroke Unit AOU "G. Martino"-Messina (P.L.L.S.); UO Neuroradiologia Ospedale Policlinico San Martino (L.C.); UO Neurologia Ospedale Policlinico San Martino (M.D.S.), Genova, Italy; Neurology Unit (I.C.), University Hospital Arcispedale S. Anna, Ferrara; Dipartimento di Scienze Biomediche (E.F.), Sperimentali e Cliniche, Neuroradiologia, Università degli Studi di Firenze, Ospedale Universitario Careggi; Unità Complessa di Neuroradiologia (R.M.), Azienda Ospedaliero-Universitaria; Dipartimento di Medicina e Chirurgia (A.P.), Università degli Studi di Parma - Programma Stroke Care, Dipartimento di Emergenza-Urgenza, Azienda Ospedaliero-Universitaria, Parma; UOSD Interventistica AOU Salerno (D.G.R.); UOC Neuroradiologia AOU Salerno (G.F.); Radiologia e Neuroradiologia diagnostica e interventistica (S.N.), IRCCS Policlinico San Matteo; UO Neurologia d'Urgenza e Stroke Unit (N. Loizzo), IRCCS Fondazione Mondino, Pavia; UO Neuroradiologia Dip Neuroscienze AZOU Ferrara (A.S.); UO Neurologia Dip Neuroscienze AZOU Ferrara (A.D.V.); Neuroradiology department ospedale di circolo- ASST Settelaghi Varese (R.A.); Stroke Unit - Azienda Ospedaliera Universitaria Integrata Verona (M. Cappellari); UO Neuroradiologia AOU Consorziale Policlinico Bari (D.S.Z.); UOC Neurologia e Stroke Unit "Puca" AOU Consorziale Policlinico Bari (M.P.); SC Neuroradiologia Diagnostica e Interventistica (L.A.), S. Corona Hospital, Pietra Ligure; UO Neuroradiologia interventistica (D.A.); Neurologia d'urgenza e Stroke Unit (S. Marcheselli), IRCCS Humanitas Research Hospital, Rozzano; UOC Neuroradiologia (M.P.G.); UOC Neurologia (G. Boero), Ospedale "SS. Annunziata", Taranto; IRCCS Neuromed (S. Mangiafico), Pozzilli (IS), Italy; Department of Clinical Neuroscience (N.A.), Karolinska Institutet, Stockholm, Sweden; Stroke Center EOC (C.W.C.), Neurocentre of Southern Switzerland; and Faculty of Biomedical Sciences (C.W.C.), Università della Svizzera Italiana, Lugano, Switzerland.
Background And Objectives: The benefit of mechanical thrombectomy (MT) in patients with acute ischemic stroke (AIS) with basilar artery occlusion (BAO) and a baseline National Institute of Health Stroke Scale (NIHSS) score <10 is unclear because this subpopulation has been substantially excluded from large clinical trials. The aim of our study was to determine whether MT ± IV thrombolysis (IVT) improves functional outcomes compared with IVT alone in patients with BAO and a NIHSS score <10.
Methods: We emulated a hypothetical trial including adult patients with BAO, a baseline NIHSS score <10, and prestroke modified Rankin scale (mRS) scores 0-2, comparing MT (±IVT) with IVT alone.
PLoS One
November 2024
Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
Background: Improving health-related quality of life (HRQoL) is an important disease management goal in persons with Multiple Sclerosis (PwMS). HRQoL decreases with increasing age and prolonged disease duration; other factors remain less understood.
Objective: To identify associations of multiple sclerosis (MS) disease characteristics and symptom burden with low HRQoL.
Front Public Health
November 2024
Injury Epidemiology and Prevention (IEP) Research Group, Turku Brain Injury Centre, Turku University Hospital and University of Turku, Turku, Finland.
Background: Low back pain (LBP) is an increasing concern amongst medical students. There is a dearth of publications regarding how the occurrence of LBP impact medical trainees' career decisions.
Objective: To determine: (i) the point and annual prevalence of LBP amongst Ugandan medical students, (ii) its associated factors, and (iii) whether the experience of LBP during clinical rotations influence medical students' career choices regarding medical practice.
Neurol Sci
November 2024
Department of Neuroanaesthesia and Neurocritical Care, National Institute of Mental Health and Neuro Sciences (NIMHANS), Neurocentre Faculty Block, 3rd Floor, Hosur road, Bengaluru, Karnataka, 560029, India.
Background: Guillain-Barré Syndrome (GBS) remains a significant contributor to acute flaccid paralysis in pediatric patients worldwide. Despite its impact, studies focusing on pediatric GBS requiring intensive care unit (ICU) management are limited. This study aimed to address this gap by exploring the clinical and outcome characteristics of pediatric GBS necessitating ICU care.
View Article and Find Full Text PDFPLOS Digit Health
November 2024
Institute for Implementation Science in Health Care, University of Zurich, Zurich, Switzerland.
Remote longitudinal studies are on the rise and promise to increase reach and reduce participation barriers in chronic disease research. However, maintaining long-term retention in these studies remains challenging. Early identification of participants with different patterns of long-term retention offers the opportunity for tailored survey adaptations.
View Article and Find Full Text PDFEur J Neurol
January 2025
Department of Uro-Neurology, The National Hospital for Neurology and Neurosurgery, London, UK.
Mult Scler Relat Disord
October 2023
Epidemiology, Biostatistics and Prevention Institute, University of Zurich (UZH), Zurich, Switzerland; Institute for Implementation Science in Health Care, University of Zurich (UZH), Zurich, Switzerland. Electronic address:
Introduction: Self-reports are a valuable and cost-effective method of data collection, though they can be influenced by bias. Limited evidence exists on the quality of self-reports by persons with multiple sclerosis (pwMS), particularly since more potent disease-modifying therapies (DMTs) have been introduced. This study aimed to assess the reliability and validity of self-reported DMT use and multiple sclerosis (MS) type in the Swiss Multiple Sclerosis Registry (SMSR) by comparing self-reports with reimbursement approval requests from the Swiss Association for Joint Tasks of Health Insurers.
View Article and Find Full Text PDFBrain Commun
September 2024
Groupe d'Imagerie Neurofonctionnelle, Institut des Maladies Neurodégénératives 5293, Centre National de la Recherche Scientifique (CNRS), University of Bordeaux, 33076 Bordeaux, France.
bioRxiv
November 2024
Groupe d'Imagerie Neurofonctionnelle, Institut des Maladies Neurodégénératives-UMR 5293, Centre national de la recherche scientifique (CNRS), CEA, University of Bordeaux, Bordeaux, France.
Stroke remains a leading cause of mortality and long-term disability worldwide, with variable recovery trajectories posing substantial challenges in anticipating post-event care and rehabilitation planning. In response, we established the NeuralCup consortium to address these challenges by benchmarking predictive models of stroke outcome through a collaborative, data-driven approach. This study presents the findings of 15 participating teams worldwide who used a comprehensive dataset including clinical and imaging data, to identify and compare predictors of motor, cognitive, and emotional outcomes one-year post-stroke.
View Article and Find Full Text PDF